Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Cell Source, Inc.
- Market Cap
- Unavailable
- Price
- $0.5813
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.23%
- Volume
- 4.3K
About
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Quick stats
Shares outstanding—
Computed float34.4M
Float / sharesUnknown
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001569340
Websitehttps://www.cell-source.com
AI Summary
AI-generated1/3
minorneutraloperations update
Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week
Cell Source presented its Veto Cell technology at the LD Micro Invitational Conference, highlighting plans to expand its clinical program.
The company intends to apply its immune tolerance platform to partially mismatched kidney transplants and off-the-shelf CAR-T cell therapy, aiming to eliminate the need for ongoing immune suppression.
Management also outlined plans to uplist from OTC PINK to the NASDAQ exchange, citing a favorable environment for clinical-stage oncology acquisitions.
Red flags
- Company is currently listed on OTC PINK, indicating higher risk and lower liquidity than major exchanges.
- No new clinical data or trial results were disclosed; the release contains only forward-looking strategic plans.